Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

243 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies.
Zanella ER, Galimi F, Sassi F, Migliardi G, Cottino F, Leto SM, Lupo B, Erriquez J, Isella C, Comoglio PM, Medico E, Tejpar S, Budinská E, Trusolino L, Bertotti A. Zanella ER, et al. Among authors: tejpar s. Sci Transl Med. 2015 Jan 28;7(272):272ra12. doi: 10.1126/scitranslmed.3010445. Sci Transl Med. 2015. PMID: 25632036 Free article.
Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.
Personeni N, Fieuws S, Piessevaux H, De Hertogh G, De Schutter J, Biesmans B, De Roock W, Capoen A, Debiec-Rychter M, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S. Personeni N, et al. Among authors: tejpar s. Clin Cancer Res. 2008 Sep 15;14(18):5869-76. doi: 10.1158/1078-0432.CCR-08-0449. Clin Cancer Res. 2008. PMID: 18794099
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S. De Roock W, et al. Among authors: tejpar s. JAMA. 2010 Oct 27;304(16):1812-20. doi: 10.1001/jama.2010.1535. JAMA. 2010. PMID: 20978259
EGFR-targeted therapy.
Vecchione L, Jacobs B, Normanno N, Ciardiello F, Tejpar S. Vecchione L, et al. Among authors: tejpar s. Exp Cell Res. 2011 Nov 15;317(19):2765-71. doi: 10.1016/j.yexcr.2011.08.021. Epub 2011 Sep 7. Exp Cell Res. 2011. PMID: 21925171 Review.
Targeted therapies: how personal should we go?
Martini M, Vecchione L, Siena S, Tejpar S, Bardelli A. Martini M, et al. Among authors: tejpar s. Nat Rev Clin Oncol. 2011 Nov 15;9(2):87-97. doi: 10.1038/nrclinonc.2011.164. Nat Rev Clin Oncol. 2011. PMID: 22083042 Review.
243 results